21 April 2026
AQSE: EDX
("EDX Medical" or the "Company")
Granting of options over ordinary shares
CAMBRIDGE, UK: EDX Medical Group plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that it has granted options over ordinary shares in the Company to directors and other members of senior management.
The intention to grant options over ordinary shares in the Company was announced to the market on April 13, 2026, as part of the announcement on the proposed application for admission to trading on AIM and proposed withdrawal of the Company's ordinary shares from AQSE. The details of the proposed share options were contained within that announcement.
Prior to the announcement on April 13, 2026, Mr Martin Walton, Deputy Chairman of the Company, already held options over 3,750,000 ordinary shares in the Company.
The announcement of April 13, 2026, stated the intention for Mr Walton to be granted options over a further 4,214,286 ordinary shares in the Company under the EDX Medical Group plc Non-Enterprise Management Incentive Plan.
The Board has agreed that Mr Walton's previous option over 3,750,000 ordinary shares in the Company should be cancelled and 're-awarded' under the EDX Medical Group plc Non-Enterprise Management Incentive Plan. This means that Mr Walton now holds options over 7,964,286 ordinary shares in the Company under the EDX Medical Group Plc Non-Enterprise Management Incentive Plan. In addition, Mr Walton holds options over 1,785,714 ordinary shares in the Company under the EDX Medical Group plc Enterprise Management Incentive Plan. Mr Walton's total options over ordinary shares in the Company now stands at 9,750,000.
The directors of the Company accept responsibility for the contents of this announcement.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Martin Walton |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Board Director / Deputy Chairman |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
EDX Medical Group plc |
|||
|
b) |
LEI |
213800BZVJZTMCZ6DJ63 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each |
|||
|
Identification code |
ISIN: GB00BNDMJS47 |
||||
|
b) |
Nature of the transaction |
Granting of options over ordinary shares under (i) the EDX Medical Group plc Non-Enterprise Management Incentive Plan and (ii) the EDX Medical Group plc Enterprise Management Incentive Plan |
|||
|
c) |
Price(s) and volume(s) |
||||
|
Price |
Volume |
||||
|
(i) NIL |
7,964,286 |
||||
|
(ii) NIL |
1,785,714 |
||||
|
d) |
Aggregated information |
||||
|
- Aggregated volume |
9,750,000 |
||||
|
- Price |
NIL |
||||
|
e) |
Date of the transaction |
2026-04-17 |
|||
|
f) |
Place of the transaction |
XOFF - Outside of a Trading Venue |
|||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Shafia Zahoor |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Chief Financial Officer |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
EDX Medical Group plc |
|||
|
b) |
LEI |
213800BZVJZTMCZ6DJ63 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each |
|||
|
Identification code |
ISIN: GB00BNDMJS47 |
||||
|
b) |
Nature of the transaction |
Granting of options over ordinary shares under (i) the EDX Medical Group plc Non-Enterprise Management Incentive Plan and (ii) the EDX Medical Group plc Enterprise Management Incentive Plan |
|||
|
c) |
Price(s) and volume(s) |
||||
|
Price |
Volume |
||||
|
(i) Nil |
43,214 |
||||
|
(ii) Nil |
2,224,286 |
||||
|
d) |
Aggregated information |
||||
|
- Aggregated volume |
2,267,500 |
||||
|
- Price |
Nil |
||||
|
e) |
Date of the transaction |
2026-04-17 |
|||
|
f) |
Place of the transaction |
XOFF - Outside of a Trading Venue |
|||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Professor Sir Christopher Evans |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Board Director / Chief Scientific Officer |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
EDX Medical Group plc |
|||
|
b) |
LEI |
213800BZVJZTMCZ6DJ63 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each |
|||
|
Identification code |
ISIN: GB00BNDMJS47 |
||||
|
b) |
Nature of the transaction |
Granting of options over ordinary shares under the EDX Medical Group plc Enterprise Management Incentive Plan |
|||
|
c) |
Price(s) and volume(s) |
||||
|
Price |
Volume |
||||
|
Nil |
1,500,000 |
||||
|
d) |
Aggregated information |
||||
|
- Aggregated volume |
1,500,000 |
||||
|
- Price |
Nil |
||||
|
e) |
Date of the transaction |
2026-04-17 |
|||
|
f) |
Place of the transaction |
XOFF - Outside of a Trading Venue |
|||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Jason Holt |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Board Director / Non-Executive Chairman |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
EDX Medical Group plc |
|||
|
b) |
LEI |
213800BZVJZTMCZ6DJ63 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each |
|||
|
Identification code |
ISIN: GB00BNDMJS47 |
||||
|
b) |
Nature of the transaction |
Granting of options over ordinary shares under the EDX Medical Group plc Non-Enterprise Management Incentive Plan |
|||
|
c) |
Price(s) and volume(s) |
||||
|
Price |
Volume |
||||
|
Nil |
1,500,000 |
||||
|
d) |
Aggregated information |
||||
|
- Aggregated volume |
1,500,000 |
||||
|
- Price |
Nil |
||||
|
e) |
Date of the transaction |
2026-04-17 |
|||
|
f) |
Place of the transaction |
XOFF - Outside of a Trading Venue |
|||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Professor Trevor Jones |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Non-Executive Director |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
EDX Medical Group plc |
|||
|
b) |
LEI |
213800BZVJZTMCZ6DJ63 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each |
|||
|
Identification code |
ISIN: GB00BNDMJS47 |
||||
|
b) |
Nature of the transaction |
Granting of options over ordinary shares under the EDX Medical Group plc Non-Enterprise Management Incentive Plan |
|||
|
c) |
Price(s) and volume(s) |
||||
|
Price |
Volume |
||||
|
Nil |
1,500,000 |
||||
|
d) |
Aggregated information |
||||
|
- Aggregated volume |
1,500,000 |
||||
|
- Price |
Nil |
||||
|
e) |
Date of the transaction |
2026-04-17 |
|||
|
f) |
Place of the transaction |
XOFF - Outside of a Trading Venue |
|||
ENDS
For enquiries, please contact:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Oberon Capital (Aquis Corporate Adviser and Broker |
|
|
Nick Lovering |
+44 (0) 20 3179 5300 |
|
Media House International |
|
|
Ramsay Smith Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609 |
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
Notes to Editors:
About EDX Medical Group plc
The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.